Results from the successful ECLS study of 12,209 Scottish patients were first released in June.
Oncimmune said the presentation of detailed information at the Barcelona gathering was an “important validation” of its technology, with the next step being a larger population-based evaluation of up to 200,000 patients.
"We are thrilled that the ECLS trial has demonstrated so clearly the potential of our EarlyCDT technology platform to transform the way cancer is diagnosed”, said Adam Hill, Oncimmune’s chief executive.
He added that the firm would work with Scottish health authorities to roll out the test more widely while also testing the technology on other forms of cancer including liver, ovarian, breast and prostate.
In mid-morning trading, the shares were up 5.5% at 96p.